It's important for multiple myeloma patients to stay up-to-speed on myeloma news because the treatment options are rapidly changing. Additionally, myeloma patients need to look ahead at their treatment options, so knowing about the latest is helpful for patients to make key life-saving decisions.
One of our goals for the Myeloma News category is to help patients understand these updates in understandable language.
In Myeloma News, we cover:
- MRD and other testing updates
- Key research findings by multiple myeloma experts and researchers
- New drug classes and treatment targets for multiple myeloma
- Findings from major myeloma meetings like ASH, ASCO, IMW, EHA and more
- Progress of myeloma therapies in development as they go through the FDA approval process
- FDA drug approvals
BLENREP is making exciting progress after being pulled from the U.S. Market as an available myeloma treatment last year.
There were a multitude of myeloma studies at IMS 2023 which analyzed the strong connection of the native immune system and the efficacy of immunotherapies.
Myeloma researchers at Mount Sinai provided 22 patients with wearable tech to detect CRS. The results were remarkable.
Dr. Joshua Richter shares at IMS 2023 how myeloma infections are being monitored and prevented.
How does multiple myeloma begin? And why does learning this information matter?
IDP-121 targets cMYC, a pivotal protein in tumorigenesis. The first patient has been successfully dosed.
Minimal residual disease testing on blood is now possible due to the test which has been validated for clinical use.
The newcomer myeloma drug iberdomide is combined with bortezomib and dexamethasone in a clinical trial and has a 100% response rate.
When combined with a stem cell transplant, the dendritic cell vaccine was safe and successful for multiple myeloma patients.